AstraZeneca said Thursday it will cut 400 jobs, with most coming at the company's Wilmington headquarters and "some field-based, non-sales roles," in other parts of the country.
The company said about 70 of the estimated 400 job cuts will come from existing vacancies. As often happens, those who want to leave can raise their hands, perhaps saving others from being let go.
None of these cuts will be at the AstraZeneca manufacturing facility in Newark, Del.
AstraZeneca said all decisions will be finalized by early December.
“This will be very difficult for our entire organization, particularly the people who are directly impacted,” Rich Fante, president, AstraZeneca U.S. & CEO, North America, said in a statement.
“However, these changes are necessary to build a leaner, more efficient organization that will enable the company to continue delivering against our mission of patient health and sustaining a strong business for years to come.”